| RPM Automotive Group Limited (RPM) ORDINARY FULLY PAID |
Consumer Discretionary |
$4 |
FY25 Results Announcement
|
28 Aug 2025 9:14AM |
$0.070 |
$0.016 |
fallen by
77.14%
|
|
RPM - Price-sensitive ASX Announcement
Full Release
Key Points
- Reported Revenue of $112.1 million, declined by 5.2% vs previous corresponding period.
- LFL Revenue increased by 1.5%, totaling $116.9 million.
- Adjusted EBITDA improved by 3.9% to $13.0 million.
- Underlying NPATA increased by 3.0% to $4.6 million.
- EBITDA Margin increased from 10.6% to 11.6%.
- Net Profit Before Tax fell by 7.6% due to increased finance costs.
- Emphasis on a shift to organic and sustainable growth strategy.
- Investment in tyre recycling facility as a strategic growth initiative.
- Focus on improving operational cash generation and free cash flow.
- Management's five strategic pillars to underpin FY26 aspirations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Raiz Invest Limited (RZI) ORDINARY FULLY PAID |
Financials |
$56 |
FY25 Results - Raiz Posts Strong Revenue Growth
|
28 Aug 2025 9:14AM |
$0.665 |
$0.535 |
fallen by
19.55%
|
|
RZI - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 15% to $24.1 million.
- Underlying EBITDA rose by 147% to $2.8 million.
- Positive UEBITDA of $2.8 million.
- Positive operating cash flows of $4 million.
- Active customers grew by 7% to 329,277.
- ARPU increased by 9% to $75.67.
- FUM increased by 30% to $1.82 billion.
- Launched new products such as Raiz Lite and Raiz Jars.
- Received multiple awards including Canstar Innovation Excellence.
- Anticipating FY26 UEBITDA between $4.5 million and $5.5 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Raiz Invest Limited (RZI) ORDINARY FULLY PAID |
Financials |
$56 |
FY25 Results - Raiz Posts Strong Revenue Growth
|
28 Aug 2025 9:14AM |
$0.665 |
$0.535 |
fallen by
19.55%
|
|
RZI - Price-sensitive ASX Announcement
Full Release
Key Points
- Raiz Invest Limited reported a 15% increase in revenue to $24.1 million for FY25.
- Active customers increased by 7% to 329,277 and ARPU increased by 9% to $75.67.
- Funds Under Management (FUM) increased by 30% to $1.82 billion.
- Underlying EBITDA grew by 147% to $2.8 million.
- Net loss after tax improved to $0.4 million from a $2.8 million loss in FY24.
- Positive free cash flow of $0.9 million was recorded.
- Raiz launched several new products including Raiz Lite and Raiz Academy.
- Strategic partnership with State Street Investment Management was announced.
- Raiz was awarded for its product innovation and customer satisfaction.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| RPM Automotive Group Limited (RPM) ORDINARY FULLY PAID |
Consumer Discretionary |
$4 |
FY25 Appendix 4E
|
28 Aug 2025 9:14AM |
$0.070 |
$0.016 |
fallen by
77.14%
|
|
RPM - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing activities decreased by 5% to $112,129,499.
- Net profit from continuing activities after tax increased by 3% to $4,642,792.
- Discontinued operations resulted in a loss, impacting NPAT negatively.
- EBITDA increased by 4% to $13 million.
- Tyre recycling program launched in H2 FY25.
- Strategic focus on B2B and B2Fleet work.
- No dividends were declared for the year.
- Plans for expansion in Victoria, Queensland, and New South Wales.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| RPM Automotive Group Limited (RPM) ORDINARY FULLY PAID |
Consumer Discretionary |
$4 |
FY25 Appendix 4E
|
28 Aug 2025 9:14AM |
$0.070 |
$0.016 |
fallen by
77.14%
|
|
RPM - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing operations was $112.13 million.
- Net profit for the year was $1.66 million.
- Total assets were $115.05 million as of June 30, 2025.
- Total equity increased to $57.75 million.
- No significant post-reporting events affecting future operations.
- Shares issued for the acquisition of Chapel Corner Tyres.
- No new business acquisitions or joint ventures.
- Consistent accounting policies were maintained.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cygnus Metals Limited (CY5) ORDINARY FULLY PAID |
Materials |
$153 |
Change of Director's Interest Notice
|
28 Aug 2025 9:13AM |
$0.084 |
$0.125 |
risen by
48.81%
|
|
| Raiz Invest Limited (RZI) ORDINARY FULLY PAID |
Financials |
$56 |
Appendix 4E and Annual Report 30 June 2025
|
28 Aug 2025 9:13AM |
$0.665 |
$0.535 |
fallen by
19.55%
|
|
RZI - Price-sensitive ASX Announcement
Full Release
Key Points
- Raiz Invest Limited reported a loss after income tax for the year ending 30 June 2025.
- The company experienced a rise in revenue driven by an increase in Funds Under Management (FUM) and active customers.
- Significant losses were recorded from discontinued operations in Southeast Asia.
- The financial position shows a stable asset base with increased current liabilities.
- The remuneration report outlines a competitive compensation framework linked to performance for executives and directors.
- Commitment to strong corporate governance and transparency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Control Bionics Limited (CBL) ORDINARY FULLY PAID |
Health Care |
$33 |
Non-Renounceable Rights Issue
|
28 Aug 2025 9:13AM |
$0.038 |
$0.074 |
risen by
94.74%
|
|
CBL - Price-sensitive ASX Announcement
Full Release
Key Points
- Non-renounceable rights issue announced to raise approximately $2.062 million.
- Offer underwritten up to $1.150 million by major shareholders and partners.
- Rights issue priced at 3.5 cents per share, offering one new share for every five held.
- Proceeds will fund NeuroStrip and NeuroNode commercialization and other operational expansions.
- Offer is open to shareholders in Australia and New Zealand.
- Shortfall in subscription to be managed by company directors.
- Offer document dispatched on 4 September 2025, closing on 15 September 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Control Bionics Limited (CBL) ORDINARY FULLY PAID |
Health Care |
$33 |
Non-Renounceable Rights Issue
|
28 Aug 2025 9:13AM |
$0.038 |
$0.074 |
risen by
94.74%
|
|
CBL - Price-sensitive ASX Announcement
Full Release
Key Points
- Non-renounceable rights issue to raise $2.062 million.
- Offer underwritten to approximately $1.150 million.
- Funds to support NeuroStrip® and NeuroNode® technologies.
- Shareholders can subscribe for one new share for every five existing shares.
- Issue price of 3.5 cents per share, at a discount to recent prices.
- Funds allocated for software development, manufacturing, clinical trials, and marketing.
- Equity underwritten by major shareholders and others.
- Underwriting fees set at 5% of the amount underwritten.
- Eligible shareholders are those registered in Australia or New Zealand.
- Intended use of funds includes strategic investments and working capital.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cygnus Metals Limited (CY5) ORDINARY FULLY PAID |
Materials |
$153 |
Application for quotation of securities - CY5
|
28 Aug 2025 9:12AM |
$0.084 |
$0.125 |
risen by
48.81%
|
|
| SomnoMed Limited (SOM) ORDINARY FULLY PAID |
Health Care |
$111 |
Full year results announcement FY25
|
28 Aug 2025 9:12AM |
$0.775 |
$0.505 |
fallen by
34.84%
|
|
SOM - Price-sensitive ASX Announcement
Full Release
Key Points
- SomnoMed reported FY25 revenue of $111.5 million, up 21.6%.
- EBITDA reached $9.2 million, exceeding market guidance.
- Milestone of treating 1 million patients achieved.
- FDA clearance for Rest Assure® device received.
- Plans to expand capacity by at least 25% in FY26.
- FY26 revenue guidance set between $119 million and $126 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SomnoMed Limited (SOM) ORDINARY FULLY PAID |
Health Care |
$111 |
Full year results announcement FY25
|
28 Aug 2025 9:12AM |
$0.775 |
$0.505 |
fallen by
34.84%
|
|
SOM - Price-sensitive ASX Announcement
Full Release
Key Points
- SomnoMed's FY25 revenue was $111.5 million, a 21.6% increase from the previous year.
- EBITDA reached $9.2 million, exceeding the market guidance.
- The company treated 1 million patients, a significant milestone.
- FDA clearance was received for Rest Assure®, a device with compliance monitoring.
- Revenue growth was strong in Europe and North America.
- Plans to expand manufacturing capacity and develop Rest Assure® further.
- FY26 revenue guidance is between $119 million and $126 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Emyria Limited (EMD) ORDINARY FULLY PAID |
Health Care |
$33 |
Emyria Expansion & Strategic Update Webinar Presentation
|
28 Aug 2025 9:12AM |
$0.050 |
$0.041 |
fallen by
18%
|
|
| SomnoMed Limited (SOM) ORDINARY FULLY PAID |
Health Care |
$111 |
Annual Report & full year results
|
28 Aug 2025 9:12AM |
$0.775 |
$0.505 |
fallen by
34.84%
|
|
SOM - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased to $111.5 million.
- Net loss after tax of $3.5 million.
- Total assets of $80.97 million and liabilities of $34.58 million.
- Significant revenue contributions from North America, Europe, and Asia Pacific.
- Focused on market expansion and financial risk management.
- Detailed notes on financial management and capital structure.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SomnoMed Limited (SOM) ORDINARY FULLY PAID |
Health Care |
$111 |
Annual Report & full year results
|
28 Aug 2025 9:12AM |
$0.775 |
$0.505 |
fallen by
34.84%
|
|
SOM - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for 2025 was $132.2 million.
- Net profit before tax was $25.3 million.
- Cash and cash equivalents increased to $17.3 million.
- Investments made in property, plant, equipment, and intangible assets.
- Comprehensive loss of $580,434 after adjustments.
- Operations cover North America, Europe, and Asia Pacific.
- Focus on expanding market presence and product offerings.
- Remuneration details for executives and directors included.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Westgold Resources Limited (WGX) ORDINARY FULLY PAID |
Materials |
$4,800 |
Dividend/Distribution - WGX
|
28 Aug 2025 9:11AM |
$3.370 |
$5.080 |
risen by
50.74%
|
|
| Invion Limited (IVX) ORDINARY FULLY PAID |
Health Care |
$3 |
Response to ASX Aware Letter
|
28 Aug 2025 9:11AM |
$0.130 |
$0.032 |
fallen by
75.38%
|
|
IVX - Price-sensitive ASX Announcement
Full Release
Key Points
- Invion received an ASX Aware Letter regarding their FDA announcement.
- The FDA granted Orphan Drug Designation for INV043 for anal cancer.
- Invion confirms compliance with ASX Listing Rule 3.1.
- The information was verified through a US-based consultant.
- Responses were authorized by Invion's Board.
- Invion holds exclusive rights to Photosoft™ technology in multiple regions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Invion Limited (IVX) ORDINARY FULLY PAID |
Health Care |
$3 |
Response to ASX Aware Letter
|
28 Aug 2025 9:11AM |
$0.130 |
$0.032 |
fallen by
75.38%
|
|
IVX - Price-sensitive ASX Announcement
Full Release
Key Points
- Invion Limited was queried by ASX regarding its announcement about the FDA granting Orphan Drug Designation for INV043 for anal cancer.
- ASX Listing Rule 3.1 requires immediate disclosure of information that can have a material effect on the entity's securities.
- Invion confirmed it became aware of the FDA decision on the afternoon of 19 August 2025.
- No prior announcement was made as the company only verified the information after online speculation and subsequently discussed a trading halt with ASX.
- Invion confirmed compliance with ASX Listing Rules, particularly Rule 3.1.
- Responses to ASX’s queries were authorized by Invion's Board.
- Invion is developing Photosoft technology for treating cancer and other diseases and holds exclusive rights in various regions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$83 |
PCG Corporate Timetable
|
28 Aug 2025 9:11AM |
$0.800 |
$0.850 |
risen by
6.25%
|
|
| Hudson Investment Group Limited (HGL) ORDINARY FULLY PAID |
Real Estate |
- |
Half Yearly Report and Accounts
|
28 Aug 2025 9:10AM |
$0.175 |
$0.175 |
fallen by
0%
|
|
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$83 |
Appendix 4G 2025
|
28 Aug 2025 9:10AM |
$0.800 |
$0.850 |
risen by
6.25%
|
|
| Codeifai Limited (CDE) ORDINARY FULLY PAID |
Industrials |
$7 |
Update on Antenna Transfer Acquisition & Timing
|
28 Aug 2025 9:10AM |
$0.017 |
$0.007 |
fallen by
58.82%
|
|
| Beamtree Holdings Limited (BMT) ORDINARY FULLY PAID |
Health Care |
$44 |
Appendix 4G and Corporate Governance Statement
|
28 Aug 2025 9:10AM |
$0.270 |
$0.150 |
fallen by
44.44%
|
|
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$83 |
Corporate Governance Statement 2025
|
28 Aug 2025 9:10AM |
$0.800 |
$0.850 |
risen by
6.25%
|
|
| Golden Horse Minerals Limited (GHM) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$102 |
DHEM Survey Supports High-Grade Mineralisation at Hopes Hill
|
28 Aug 2025 9:10AM |
$0.450 |
$0.470 |
risen by
4.44%
|
|
GHM - Price-sensitive ASX Announcement
Full Release
Key Points
- DHEM survey identifies deeper high-grade targets at Hopes Hill.
- Recent diamond drilling intersects high-grade mineralisation.
- Additional drilling rigs mobilised to expedite exploration.
- Encouraging soil sampling results lead to new drill targets.
- Plans for regional drilling to test high-priority targets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
